PATH and partners launch statement on single-dose HPV vaccination
In December 2022, the World Health Organization endorsed a single-dose schedule for HPV vaccination for the primary target age group (9-14 years-old). Since then, additional data continue to build the evidence base in support of its use.
As global leaders gather at the World Health Assembly to assess progress and chart priorities, PATH has joined other global partners in signing onto a statement to raise awareness about the potential impact of a single-dose HPV vaccine schedule. As the world rallies to recover from disruptions to immunization coverage caused by the COVID-19 pandemic and other global crises, WHO’s endorsement represents a critical opportunity to reach more girls and protect more women against cervical cancer.
From advancing new vaccine candidates to optimizing programmatic impact, PATH is working to increase vaccine access to protect as many girls as possible.